Type I interferon therapy and its role in autoimmunity

References

• Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev. 2004; 202:8–32.
   PubMed Web of Science ®Google Scholar
• Stewart TA. Neutralizing interferon α as a therapeutic approach to autoimmune diseases. Cytokine Growth Factor Rev. 2003; 14:139–154.
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Bannink M, Van Gool AR, Kruit WH, Stoter G. Side effects of interferon-alpha therapy. Pharm World Sci. 2005; 27:423–431.
   PubMed Web of Science ®Google Scholar
• Prior C, Oroszy S, Oberaigner W, Schenk E, Kummer F, Aigner K, Hausmaninger H, Peschel C, Huber H. Adjunctive interferonalpha-2c in stage IIIB/IV small-cell lung cancer: A phase III trial. Eur Respir J. 1997; 10:392–396.
   PubMed Web of Science ®Google Scholar
• Edwards L, Berman B, Rapini RP, Whiting DA, Tyring S, HTJr, Eyre SP, Tanner DJ, Taylor EL, Peets E. Treatment of cutaneous squamous cell carcinomas by intralesional interferon alfa-2b therapy. Arch Dermatol. 1992; 128:1486–1489Greenway.
   PubMed Web of Science ®Google Scholar
• Gueudry J, Wechsler B, Terrada C, Gendron G, Cassoux N, Fardeau C, Lehoang P, Piette JC, Bodaghi B. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease. Am J Ophthalmol. 2008; 146:837–844.
   PubMed Web of Science ®Google Scholar
• Jumbou O, N'Guyen JM, Tessier MH, Legoux B, Dreno B. Long-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interferon-alfa. Br J Dermatol. 1999; 140:427–431.
   PubMed Web of Science ®Google Scholar
• Thivolet J, Nicolas JF, Kanitakis J, Lyonnet S, Chouvet B. Recombinant interferon alpha 2a is effective in the treatment of discoid and subacute cutaneous lupus erythematosus. Br J Dermatol. 1990; 122:405–409.
   Google Scholar
• Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening haemangioma of infancy. N Engl J Med. 1992; 326:1456–1463.
   PubMed Web of Science ®Google Scholar
• Marotta G, Frassoldati A, Zinzani P, Annino L, Brugiatelli M, Ambrosetti A, Lenoci M, Federico M, Foa R, Lauria F. Italian Cooperative group for HCL (ICGHCL). Role of interferon-alpha administration after 2-deoxycoformycin in the treatment of hairy cell leukaemia patients. Eur J Haematol. 2006; 77:109–113.
   Google Scholar
• Schaar CG, Kluin-Nelemans HC, Te Marvelde C, le Cessie S, Breed WP, Fibbe WE, van Deijk WA, Fickers MM, Roozendaal KJ, Wijermans PW. Dutch-Belgian Hemato-Oncology Cooperative Group HOVON. Interferon-alpha as maintenance therapy in patients with multiple myeloma. Ann Oncol. 2005; 16:634–639.
   PubMed Web of Science ®Google Scholar
• Avilés A, Díaz-Maqueo JC, Talavera A, Nambo MJ, García EL. Maintenance therapy with interferon alfa 2b in Hodgkin's disease. Leuk Lymphoma. 1998; 30:651–656.
   PubMed Web of Science ®Google Scholar
• Armitage AE, Armitage JD, Armitage JO. Alpha-interferon for relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant. 2006; 38:701–702.
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Mellgren SI, Svenningsson A, Elovaara I, Frederiksen JL, Beiske AG, Myhr KM, Søgaard LV, Olsen IC, Wollheim M. NORdic trial of oral methylprednisolone as add-on therapy to interferon beta-1a for treatment of relapsing-remitting multiple sclerosis (NORMIMS study): A randomised, placebo-controlled trial. Lancet Neurol 2009;8:519-529Sberg-.
   Google Scholar
• Rockey DC. Antifibrotic therapy in chronic liver disease. Clin Gastroenterol Hepatol. 2005; 3:95–107.
   PubMed Web of Science ®Google Scholar
• Charles C, Clements P, Furst DE. Systemic sclerosis: Hypothesis-driven treatment strategies. Lancet. 2006; 367:1683–1691.
   PubMed Web of Science ®Google Scholar
• Walder-Hantich B, Jabkowski J, MacHeiner W, Salmhofer W, Zahel B, Pinter G, Herold M, Klein G, Fritsch PO. Interferongamma in the treatment of systemic sclerosis: A randomized controlled multicentre trial. Br J Dermatol. 1998; 139:639–648.
   Google Scholar
• Boutin C, Viallat JR, Van Zandwijk N, Douillard JT, Paillard JC, Guerin JC, Mignot P, Migueres J, Varlet F, Jehan A. Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma. Cancer. 1991; 67:2033–2037.
   PubMed Web of Science ®Google Scholar
• Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, TEJr.. Idiopathic Pulmonary Fibrosis Study Group. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004; 350:125–133Kg.
   PubMed Web of Science ®Google Scholar
• Condos R, Rom WN, Schluger NW. Treatment of multidrugresistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet. 1997; 349:1513–1515.
   PubMed Web of Science ®Google Scholar
• Hanifin JM, Schneider LC, Leung DY, Ellis CN, Jaffe HS, Izu AE, Bucalo LR, Hirabayashi SE, Tofte SJ, Cantu-Gonzales G. Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol. 1993; 28:189–197.
   PubMed Web of Science ®Google Scholar
• Vervoordeldonk MJ, Aalbers CJ, Tak PP. Interferon beta for rheumatoid arthritis: New clothes for an old kid on the block. Ann Rheum Dis. 2009; 68:157–158.
   Google Scholar
• Borg FAY, Isenberg DA. Syndromes and complications of interferon therapy. Curr Opin Rheumatol. 2007; 19:61–66.
   Web of Science ®Google Scholar
• Krause I, Valesini G, Scrivo R, Shoenfeld Y. Autoimmune aspects of cytokine and anticytokine therapies. Am J Med. 2003; 115:390–397.
   PubMed Web of Science ®Google Scholar
• Preziati D, La Rosa L, Covini G, Marcelli R, Rescalli S, Persani L, Del Ninno E, Meroni PL, Colombo M, Beck-Peccoz P. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol. 1995; 132:587–593.
   PubMed Web of Science ®Google Scholar
• Mandac JC, Chaudhry S, Sherman KE, Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: Towards a new classification. Hepatology. 2006; 43:661–672.
   PubMed Web of Science ®Google Scholar
• Doi F, Kakizaki S, Takagi H, Murakami M, Sohara N, Otsuka T, Abe T, Mori M. Long-term outcome of interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. Liver Int. 2005; 25 2: 242–246.
   Google Scholar
• Monzani F, Caraccio N, Dardano A, Ferrannini E. Thyroid autoimmunity and dysfunction associated with type I interferon therapy. Clin Exp Med. 2004; 3:199–210.
   PubMed Web of Science ®Google Scholar
• Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F, Vazquez R, Ocete E, Olea N, Salmeron J. Increased risk of autoimmune thyroid disease in hepatitis C vs. hepatitis B before, during, and after discontinuing interferon therapy. Arch Intern Med. 1998; 158:1445–1448.
   PubMed Web of Science ®Google Scholar
• Tran A, Quaranta JF, Benzaken S, Thiers V, Chau HT, Hastier P, Regnier D, Dreyfus G, Pradier C, Sadoul JL. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology. 1993; 18:253–257.
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Sorvillo F, Piscopo M, Morisco F, Cioffi M, Stornaiuolo G, Gaeta GB, Molinari AM, Lazarus JH, Amato G, Carella C. Innate and acquired immune system in patients developing interferon-a-related autoimmune thyroiditis: A prospective study. J Clin Endocrinol Metab. 2005; 90:4138–4144.
   PubMed Web of Science ®Google Scholar
• Cozzolongo R, Betterle C, Fabris P, Paola Albergoni M, Lanzilotta E, Manghisi OG. Onset of type 1 diabetes mellitus during peginterferon a-2b plus ribavirin treatment for chronic hepatitis C. Eur J Gastroenterol Hepatol. 2006; 18:689–692.
   PubMed Web of Science ®Google Scholar
• Fabris P, Floreani A, Tositti G. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther. 2003; 18:549–558.
   PubMed Web of Science ®Google Scholar
• Gota C, Calabrese L. Induction of clinical autoimmune disease by therapeutic interferon-alpha. Autoimmunity. 2003; 36:511–518.
   PubMed Web of Science ®Google Scholar
• Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000; 43:1431–1442.
   PubMed Web of Science ®Google Scholar
• Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, Nishioji K, Katagishi T, Nakagawa Y, Tada H, Sawa Y, Mizuno M, Kagawa K, Kashima K. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol. 1996; 25:283–291.
   PubMed Web of Science ®Google Scholar
• Nesher G, Ruchlemer R. Alpha-interferon-induced arthritis: Clinical presentation, treatment and prevention. Semin Arthritis Rheum. 1998; 27:360–365.
   PubMed Web of Science ®Google Scholar
• Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999; 160:736–755.
   PubMed Web of Science ®Google Scholar
• Yanardag H, Pamuk ON, Karayel T. Cutaneous involvement in sarcoidosis: Analysis of the features in 170 patients. Respir Med. 2003; 97:978–982.
   PubMed Web of Science ®Google Scholar
• Alazemi S, Campos MA. Interferon-induced sarcoidosis. Int J Clin Pract. 2006; 60:201–211.
   PubMed Web of Science ®Google Scholar
• Yee AM, Buyon JP, Yip YK. Interferon alpha associated with systemic lupus erythematosus is not intrinsically acid labile. J Exp Med. 1989; 169:987–993.
   Google Scholar
• Yee AM, Yip YK, Fischer HD, Buyon JP. Serum activity that confers acid lability to alpha-interferon in systemic lupus erythematosus: Its association with disease activity and its independence from circulating alpha-interferon. Arthritis Rheum. 1990; 33:563–568.
   PubMed Web of Science ®Google Scholar
• Pascual V, Banchereau J, Palucka AK. The central role of dendritic cells and interferon α in SLE. Curr Opin Rheumatol. 2003; 15:548–556.
   PubMed Web of Science ®Google Scholar
• Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003; 197:711–723.
   PubMed Web of Science ®Google Scholar
• Rönnblom L, Alm GV, Eloranta ML. Type I interferon and lupus. Curr Opin Rheumatol. 2009; 21:471–477.
   PubMed Web of Science ®Google Scholar
• Kanta H, Mohan C. Three checkpoints in lupus development: Central tolerance in adaptive immunity, peripheral amplification by innate immunity and end- organ inflammation. Genes Immun. 2009; 10:390–396.
   Google Scholar
• Nacionales DC, Kelly-Scumpia KM, Lee PY, Weinstein JS, Lyons R, Sobel E, Satoh M, Reeves WH. Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum. 2007; 56:3770–3783.
   PubMed Web of Science ®Google Scholar
• Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science. 2001; 294:1540–1543.
   PubMed Web of Science ®Google Scholar
• Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest. 2005; 115:407–417.
   PubMed Web of Science ®Google Scholar
• Niewold TB. Interferon alpha-induced lupus. Proof of principle. J Clin Rheumatol. 2008; 14:131–132.
   PubMed Web of Science ®Google Scholar
• Dall'era MC, Cardarelli PM, Preston BT, Witte A, JCJr. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis. 2005; 64:1692–1697Davis.
   PubMed Web of Science ®Google Scholar
• Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, Dong X, Chen W, Kim MH, Weng HH, Furst DE, Gorn A, McMahon M, Taylor M, Brahn E, Hahn BH, Tsao BP. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 2006; 54:2951–2962.
   PubMed Web of Science ®Google Scholar
• Tang J, Gu Y, Zhang M, Ye S, Chen X, Guo Q, Qian J, Bao C, Chen S, Shen N. Increased expression of the type I interferon-inducible gene, lymphocyte antigen 6 complex locus E, in peripheral blood cells is predictive of lupus activity in a large cohort of Chinese lupus patients. Lupus. 2008; 17:805–813.
   Google Scholar
• Bauer JW, Baechler EC, Petri M, Batliwalla FM, Crawford D, Ortmann WA, Espe KJ, Li W, Patel DD, Gregersen PK, Behrens TW. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med. 2006; 3:e491.
   PubMed Web of Science ®Google Scholar
• Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005; 52:1491–1503.
   PubMed Web of Science ®Google Scholar
• Niewold TB, Adler JE, Glenn SB, Lehman TJ, Harley JB, Crow MK. Age- and sex-related patterns of serum interferon-alpha activity in lupus families. Arthritis Rheum. 2008; 58:2113–2119.
   PubMedGoogle Scholar
• Kariuki SN, Kirou KA, MacDermott EJ, Barillas-Arias L, Crow MK, Niewold TB. Cutting edge: Autoimmune disease risk variant of STAT4 confers increased sensitivity to IFNα in lupus patients in vivo. J Immunol. 2009; 182:34–38.
   PubMed Web of Science ®Google Scholar
• Criswell LA. The genetic contribution to systemic lupus erythematosus. Bull NYU Hosp Jt Dis. 2008; 66:176–183.
   PubMedGoogle Scholar
• Sigurdsson S, Nordmark G, Garnier S, Grundberg E, Kwan T, Nilsson O, Eloranta ML, Gunnarsson I, Svenungsson E, Sturfelt G, Bengtsson AA, Jönsen A, Truedsson L, Rantapää-Dahlqvist S, Eriksson C, Alm G, Göring HH, Pastinen T, Syvänen AC, Rönnblom L. A common STAT4 risk haplotype for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA production and shows additive effects with two IRF5 risk alleles. Hum Mol Genet. 2008; 17:2868–2876.
   PubMed Web of Science ®Google Scholar
• Landolt-Marticorena C, Bonventi G, Lubovich A, Ferguson C, Unnithan T, Su J, Gladman DD, Urowitz M, Fortin PR, Wither J. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis. 2009; 68:1440–1446.
   PubMed Web of Science ®Google Scholar
• Denny MF, Thacker S, Mehta H, Somers EC, Dodick T, Barrat FJ, McCune WJ, Kaplan MJ. Interferon-{alpha} promotes abnormal vasculogenesis in lupus: A potential pathway for premature atherosclerosis. Blood. 2007; 110:2907–2915.
   PubMed Web of Science ®Google Scholar
• Lee PY, Li Y, Richards HB, Chan FS, Zhuang H, Narain S, Butfiloski EJ, Sobel ES, Reeves WH, Segal MS. Type I Interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum. 2007; 56:3759–3769.
   PubMed Web of Science ®Google Scholar